Literature DB >> 10986805

Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine.

D R Rosenberg1, F P MacMaster, M S Keshavan, K D Fitzgerald, C M Stewart, G J Moore.   

Abstract

OBJECTIVE: To measure in vivo neurochemical changes in the caudate nucleus in pediatric obsessive-compulsive disorder (OCD) before and after treatment.
METHOD: Single-voxel proton magnetic resonance spectroscopic (1H-MRS) examinations of the left caudate were conducted in 11 psychotropic drug-naive children, aged 8 to 17 years, with OCD before and after 12 weeks of monotherapy with the selective serotonin reuptake inhibitor paroxetine (10-60 mg/day) and 11 healthy children aged 8 to 17 years. A different sample of 8 pediatric OCD patients and 8 healthy children had a 1H-MRS examination of occipital cortex.
RESULTS: Caudate glutamatergic concentrations (Glx) were significantly greater in treatment-naive OCD patients than in controls but declined significantly after paroxetine treatment to levels comparable with those of controls. Decrease in caudate Glx was associated with decrease in OCD symptom severity. Occipital Glx did not differ between OCD patients and controls.
CONCLUSIONS: These preliminary findings provide new evidence of Glx abnormalities in the caudate nucleus in pediatric OCD and suggest that paroxetine treatment may be mediated by a serotonergically modulated reduction in caudate Glx.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10986805     DOI: 10.1097/00004583-200009000-00008

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  86 in total

1.  Evidence for cortical inhibitory and excitatory dysfunction in obsessive compulsive disorder.

Authors:  Margaret A Richter; Danilo R de Jesus; Sylco Hoppenbrouwers; Melissa Daigle; Jasna Deluce; Lakshmi N Ravindran; Paul B Fitzgerald; Zafiris J Daskalakis
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

2.  Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder.

Authors:  Vladimir Coric; Snezana Milanovic; Suzanne Wasylink; Pinal Patel; Robert Malison; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2003-03-26       Impact factor: 4.530

3.  Serum brain-derived neurotrophic factor predicts responses to escitalopram in chronic posttraumatic stress disorder.

Authors:  William Berger; Akhil Mehra; Maryann Lenoci; Thomas J Metzler; Christian Otte; Gary Tarasovsky; Synthia H Mellon; Owen M Wolkowitz; Charles R Marmar; Thomas C Neylan
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-07-17       Impact factor: 5.067

4.  Glutamate system genes associated with ventral prefrontal and thalamic volume in pediatric obsessive-compulsive disorder.

Authors:  Paul Daniel Arnold; Frank P Macmaster; Gregory L Hanna; Margaret A Richter; Tricia Sicard; Eliza Burroughs; Yousha Mirza; Phillip C Easter; Michelle Rose; James L Kennedy; David R Rosenberg
Journal:  Brain Imaging Behav       Date:  2009-03-01       Impact factor: 3.978

Review 5.  Predictors of pharmacotherapy response in anxiety disorders.

Authors:  Damiaan Denys; Femke de Geus
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

6.  Glutamate in Pediatric Obsessive-Compulsive Disorder and Response to Cognitive-Behavioral Therapy: Randomized Clinical Trial.

Authors:  Joseph O'Neill; John Piacentini; Susanna Chang; Ronald Ly; Tsz M Lai; Casey C Armstrong; Lindsey Bergman; Michelle Rozenman; Tara Peris; Allison Vreeland; Ross Mudgway; Jennifer G Levitt; Noriko Salamon; Stefan Posse; Gerhard S Hellemann; Jeffry R Alger; James T McCracken; Erika L Nurmi
Journal:  Neuropsychopharmacology       Date:  2017-04-04       Impact factor: 7.853

7.  An Examination of Rostral Anterior Cingulate Cortex Function and Neurochemistry in Obsessive-Compulsive Disorder.

Authors:  Brian P Brennan; Olga Tkachenko; Zachary J Schwab; Richard J Juelich; Erin M Ryan; Alison J Athey; Harrison G Pope; Michael A Jenike; Justin T Baker; William D S Killgore; James I Hudson; J Eric Jensen; Scott L Rauch
Journal:  Neuropsychopharmacology       Date:  2015-02-09       Impact factor: 7.853

8.  N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.

Authors:  Daniel L Lafleur; Christopher Pittenger; Ben Kelmendi; Tom Gardner; Suzanne Wasylink; Robert T Malison; Gerard Sanacora; John H Krystal; Vladimir Coric
Journal:  Psychopharmacology (Berl)       Date:  2005-12-22       Impact factor: 4.530

9.  Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study.

Authors:  Paul D Arnold; David R Rosenberg; Emanuela Mundo; Subi Tharmalingam; James L Kennedy; Margaret A Richter
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

10.  Long-term outcome in adults with obsessive-compulsive disorder.

Authors:  Michael H Bloch; Christy Green; Stephen A Kichuk; Philip A Dombrowski; Suzanne Wasylink; Eileen Billingslea; Angeli Landeros-Weisenberger; Benjamin Kelmendi; Wayne K Goodman; James F Leckman; Vladimir Coric; Christopher Pittenger
Journal:  Depress Anxiety       Date:  2013-03-26       Impact factor: 6.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.